Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. $(ACOG)$. The company launched ZUNVEYL (benzgalantamine) to the U.S. long-term care market in March 2025, with positive feedback and successful patient outcomes reported. Medicare reimbursement was secured, enhancing patient access. For more information, visit newsfilecorp.com/release/166354.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 252571) on May 19, 2025, and is solely responsible for the information contained therein.